Spots Global Cancer Trial Database for tegavivint
Every month we try and update this database with for tegavivint cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma | NCT05797805 | Advanced Hepato... | Tegavivint Pembrolizumab | 18 Years - | Iterion Therapeutics | |
| Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 | NCT03459469 | Desmoid Tumor | Tegavivint | 18 Years - | Iterion Therapeutics | |
| Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | NCT05755087 | Recurrent Diffu... Recurrent Diffu... Recurrent High ... Recurrent High ... Refractory Diff... Refractory Diff... Refractory High... Refractory High... Transformed Ind... | Biospecimen Col... Computed Tomogr... Positron Emissi... Tegavivint | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma | NCT05797805 | Advanced Hepato... | Tegavivint Pembrolizumab | 18 Years - | Iterion Therapeutics | |
| Tegavivint for the Treatment of Relapsed or Refractory Leukemia | NCT04874480 | Recurrent Leuke... Refractory Leuk... | Decitabine Tegavivint | 18 Years - | M.D. Anderson Cancer Center | |
| Tegavivint for the Treatment of Relapsed or Refractory Leukemia | NCT04874480 | Recurrent Leuke... Refractory Leuk... | Decitabine Tegavivint | 18 Years - | M.D. Anderson Cancer Center | |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | NCT04851119 | Colorectal Carc... Endometrial Car... Melanoma Neuroblastoma Ovarian Carcino... Pancreatic Duct... Recurrent Desmo... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Malig... Recurrent Non-H... Recurrent Osteo... Refractory Desm... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Non-... Refractory Oste... Solid Pseudopap... Wilms Tumor | Biospecimen Col... Dual X-ray Abso... Tegavivint X-Ray Imaging | 12 Months - 30 Years | Children's Oncology Group | |
| Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | NCT05755087 | Recurrent Diffu... Recurrent Diffu... Recurrent High ... Recurrent High ... Refractory Diff... Refractory Diff... Refractory High... Refractory High... Transformed Ind... | Biospecimen Col... Computed Tomogr... Positron Emissi... Tegavivint | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer | NCT04780568 | Metastatic Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Osimertinib Tegavivint | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer | NCT04780568 | Metastatic Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Osimertinib Tegavivint | 18 Years - | Ohio State University Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
